The National Genomic Test Directory for Cancer  specifies the genomic tests commissioned by NHS England for cancer, eligibility criteria, and how to order them.

The solid tumour tests we provide may inform diagnosis and prognosis across a diverse range of cancer types, as well as revealing gene variants which provide treatment opportunities via targeted therapies.

Most tests in the Cancer Test Directory are provided by one of the regional laboratories that are part of the Central and South Genomic Laboratory Hub (C&S GLH). Initial test requests will be triaged by the nearest laboratory to clinicians, who will ensure the sample is sent to the relevant lab. A small number of specialised tests are not provided by the C&S GLH. These tests will be sent to other laboratories across England, as part of the wider Genomic Medicine Service network. This will not affect the ordering or referral process.

Whole Genome Sequencing (WGS) is commissioned by NHS England for a sub-group of patients with solid cancers. More information and test information sheets can be accessed by clicking here.

Further information about cancer tests provided within your local Genomic Laboratory Hub lab can be found on the relevant websites below.

Date Test Code Test Name Target Gene(s) [essential] Test Scope Technology Further Eligibility Criteria Essential targets only
6 March 2026 M218.1 Multi-target NGS panel – small variant (BRCA1, BRCA2) for somatic/tissue testing BRCA1, BRCA2 Small variant detection Panel Patient is eligible for NICE approved PARP inhibitor and has a diagnosis of metastatic castration-resistant prostate cancer. Somatic analysis should be performed first, germline analysis (R444.2) should only be performed should there be insufficient tissue, or the somatic analysis has failed.
Date Test Code Test Name Target Gene(s) [essential] Test Scope Technology Further Eligibility Criteria Essential targets only
6 March 2026 M218.1 Multi-target NGS panel – small variant (BRCA1, BRCA2) for somatic/tissue testing BRCA1, BRCA2 Small variant detection Panel Patient is eligible for NICE approved PARP inhibitor and has a diagnosis of metastatic castration-resistant prostate cancer. Somatic analysis should be performed first, germline analysis (R444.2) should only be performed should there be insufficient tissue, or the somatic analysis has failed.
Date Test Code Test Name Target Gene(s) [essential] Test Scope Technology Further Eligibility Criteria Essential targets only
6 March 2026 M218.1 Multi-target NGS panel – small variant (BRCA1, BRCA2) for somatic/tissue testing BRCA1, BRCA2 Small variant detection Panel Patient is eligible for NICE approved PARP inhibitor and has a diagnosis of metastatic castration-resistant prostate cancer. Somatic analysis should be performed first, germline analysis (R444.2) should only be performed should there be insufficient tissue, or the somatic analysis has failed.